PARP1 and cancer: As a consequence, PARP1 inhibitors are today registered as monotherapy in cancers bearing DNA-repair deficiencies [28–34] and the strong rational to combine selected cytotoxics (especially alkylators) with PARP1 inhibitors has to face the risk of myelotoxicity.